Brisbane Clinical Trials
The Inhaled Vaccine Study
The study drug is a potential new COVID-19 vaccine.
nights
1 vaccine visit + 1 phone call + 6 visits
11 previous cohorts of this clinical trial were completed at Nucleus Network in 2021 and 2022. Previous cohorts included administration of the vaccine via intramuscular injection and intranasal administration (with a nasal spray).
You will not be exposed to or infected with COVID-19 during this study.
The study drug is administered via a nebuliser and will be inhaled through the mouth. This administration method would make the COVID-19 vaccine more accessible to people with fear of needles.
Eligibility
Biological Sex Healthy people
Age 18-60 years old
BMI 18 - 32kg/m²
Weight > 50kg
Medical History No significant medical history
Medication Not taking any medication
Vaccine History Fully vaccinated against COVID-19 (cannot have received any COVID-19 vaccines in the past 6 months)
Smoking History Non-smokers and casual smokers only (no more than 5 cigarettes/week)